Latrepirdine (Dimebon TM) was originally marketed as a non-selective antihistamine in Russia. It was repurposed as an effective treatment for patients suffering from Alzheimer’s disease (AD) and ...

Future Neurology. 2010;5(5):645-651. In the mouse model of senescence, senescence-accelerated mouse prone-10 mice (aged 16 months) exhibited behavior and memory deficiency, exploratory behavior ...

(HealthDay News) — Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate ...

The second of two studies on latrepirdine demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative ...

Recent studies suggest that α-syn exists as a stable helically folded tetramer that must undergo destabilization before misfolding and formation of the fibrillar aggregates that are observed in ...

Separate Phase 3 Safety Study Demonstrates Dimebon's Tolerability When Used Alone or in Combination with Approved Alzheimer's Disease Medicines Medivation to Hold Investor Call at 8:30 a.m. EST NEW ...

As recently as January, tests to use Medivation's ($MDVN) Dimebon (latrepirdine) as a treatment for Alzheimer's disease were deemed to be an abject failure. But today ...

Scientists have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer’s disease effectively stopped the progression of memory deterioration and brain ...

Future Neurology. 2010;5(5):645-651. Current treatments and drug therapies approved for use in AD attempt to provide symptomatic relief via cholinergic mechanisms or by altering NMDA-receptor ...

The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep ...

(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's ...

The second of two studies on latrepirdine demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease and other neurodegenerative conditions. The second of ...